Mbiomics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
43
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$35M
- Investors
-
5
Mbiomics General Information
Description
Operator of a microbiome research firm intended to transform microbiome research, diagnostics, and therapeutics. The company delivers a high-throughput, low-cost platform for dynamic and real-time analysis and quantification of the human gut microbiome, offering informed precision diagnostics and targeted therapies, enabling patients to improve their lives through novel approaches to lead a healthy life.
Contact Information
Website
www.mbiomics.comCorporate Office
- Floriansbogen 2-4
- 82061 Neuried
- Germany
Corporate Office
- Floriansbogen 2-4
- 82061 Neuried
- Germany
Mbiomics Timeline
Mbiomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series A) | 28-Apr-2026 | $35M | Completed | Clinical Trials - Phase 2 | ||
| 1. Accelerator/Incubator | 01-Jan-2023 | Completed | Clinical Trials - Phase 2 |
Mbiomics Comparisons
Industry
Financing
Details
Mbiomics Competitors (2)
One of Mbiomics’s 2 competitors is MRM Health, a Venture Capital-Backed company based in Ghent, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MRM Health | Venture Capital-Backed | Ghent, Belgium | ||||
| Microbiotica | Venture Capital-Backed | Cambridge, United Kingdom |
Mbiomics Patents
Mbiomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026139517-A1 | Modular system and method for quantifying target polynucleotides using barcoded oligonucleotides with enhanced flexibility and error recovery | Pending | 27-Dec-2024 | ||
| EP-4722382-A1 | Purifying hybridized rna polynucleotides | Pending | 02-Oct-2024 | ||
| US-20260092268-A1 | Purifying hybridized rna polynucleotides using a washing buffer with no ethanol to remove unbound oligonucleotides | Pending | 02-Oct-2024 | ||
| WO-2026064418-A1 | Compositions of bacterial consortium and methods of use | Pending | 18-Sep-2024 | ||
| EP-4460578-A1 | Method of determining a quantitative fingerprint of a subset of bacteria in a person's gastrointestinal microbiome | Pending | 14-Jan-2022 | C12Q1/6816 |
Mbiomics Signals
Mbiomics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bayern Kapital | Venture Capital | Minority | ||
| High-Tech Gründerfonds | Venture Capital | Minority | ||
| MIG AG | Venture Capital | Minority | ||
| MIG Capital | Family Office | Minority | ||
| German Accelerator | Accelerator/Incubator |
Mbiomics FAQs
-
When was Mbiomics founded?
Mbiomics was founded in 2020.
-
Where is Mbiomics headquartered?
Mbiomics is headquartered in Neuried, Germany.
-
What is the size of Mbiomics?
Mbiomics has 43 total employees.
-
What industry is Mbiomics in?
Mbiomics’s primary industry is Drug Discovery.
-
Is Mbiomics a private or public company?
Mbiomics is a Private company.
-
What is Mbiomics’s current revenue?
The current revenue for Mbiomics is .
-
How much funding has Mbiomics raised over time?
Mbiomics has raised $35M.
-
Who are Mbiomics’s investors?
Bayern Kapital, High-Tech Gründerfonds, MIG AG, MIG Capital, and German Accelerator have invested in Mbiomics.
-
Who are Mbiomics’s competitors?
MRM Health and Microbiotica are competitors of Mbiomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process